[Form 4] DexCom, Inc. Insider Trading Activity
Kyle Malady, a director of DexCom, Inc. (DXCM), reported a sale of common stock executed on 09/05/2025 under a previously adopted 10b5-1 trading plan. The Form 4 shows 667 shares were sold at $80.86 per share pursuant to the 10b5-1 plan adopted on 06/06/2025 to allow orderly dispositions. After the reported sale, Mr. Malady beneficially owned 22,667 shares, which include 5,192 unvested restricted stock units granted on 05/08/2025 that vest on the earlier of the one-year anniversary of the grant or DexCom鈥檚 2026 Annual Meeting of Stockholders.
Kyle Malady, direttore di DexCom, Inc. (DXCM), ha dichiarato la vendita di azioni ordinarie eseguita il 09/05/2025 nell'ambito di un piano di negoziazione 10b5-1 precedentemente adottato. Il Modulo 4 indica che sono state vendute 667 azioni al prezzo di $80,86 per azione conformemente al piano 10b5-1 adottato il 06/06/2025 per consentire disposizioni ordinate. Dopo la vendita riportata, il sig. Malady deteneva beneficiariamente 22.667 azioni, che includono 5.192 unit脿 di azioni vincolate non maturate (RSU) concesse il 05/08/2025 e che maturano alla scadenza del primo anniversario della concessione o, se anticipata, all'Assemblea Annuale degli Azionisti DexCom 2026.
Kyle Malady, director de DexCom, Inc. (DXCM), inform贸 la venta de acciones ordinarias realizada el 05/09/2025 en virtud de un plan de negociaci贸n 10b5-1 adoptado previamente. El Formulario 4 muestra que se vendieron 667 acciones a $80.86 por acci贸n conforme al plan 10b5-1 adoptado el 06/06/2025 para permitir disposiciones ordenadas. Tras la venta informada, el Sr. Malady pose铆a en beneficio 22,667 acciones, que incluyen 5,192 unidades restringidas de acciones no devengadas (RSU) otorgadas el 08/05/2025 y que devengar谩n en la fecha anterior entre el primer aniversario de la concesi贸n o la Junta Anual de Accionistas de DexCom de 2026.
DexCom, Inc.(DXCM) 鞚挫偓鞚� Kyle Malady電� 2025雲� 9鞗� 5鞚检棎 鞚挫爠鞐� 毂勴儩霅� 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 氤错喌欤茧ゼ 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 2025雲� 6鞗� 6鞚� 毂勴儩霅� 歆堨劀 鞛堧姅 觳橂秳鞚� 項堨毄頃橁赴 鞙勴暅 10b5-1 瓿勴殟鞐� 霐半澕 欤茧嫻 $80.86鞐� 667欤缄皜 毵る弰霅� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 毵り皝 鞚错泟 Malady 鞌姅 齑� 22,667欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞐赴鞐愲姅 2025雲� 5鞗� 8鞚检棎 攵�鞐悩鞏� 鞎勳 頇曥爼霅橃 鞎婌潃 5,192欤检潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� 韽暔霅橃柎 鞛堦碃, 頃措嫻 RSU電� 攵�鞐澕搿滊秬韯� 1欤茧厔 霕愲姅 DexCom鞚� 2026雲� 鞐半 欤检＜齑濏殞 欷� 雿� 鞚措ジ 鞁滌爯鞐� 旆摑霅╇媹雼�.
Kyle Malady, administrateur de DexCom, Inc. (DXCM), a d茅clar茅 une cession d'actions ordinaires r茅alis茅e le 05/09/2025 dans le cadre d'un plan de n茅gociation 10b5-1 adopt茅 ant茅rieurement. Le formulaire 4 indique que 667 actions ont 茅t茅 vendues 脿 80,86 $ par action conform茅ment au plan 10b5-1 adopt茅 le 06/06/2025 afin de permettre des cessions ordonn茅es. Apr猫s la vente signal茅e, M. Malady d茅tenait 脿 titre b茅n茅ficiaire 22 667 actions, qui comprennent 5 192 unit茅s d'actions restreintes non acquises (RSU) attribu茅es le 08/05/2025 et qui deviendront acquises au plus t么t 脿 la date du premier anniversaire de l'attribution ou lors de l'assembl茅e annuelle des actionnaires de DexCom en 2026.
Kyle Malady, Direktor von DexCom, Inc. (DXCM), meldete einen Verkauf von Stammaktien, der am 05.09.2025 im Rahmen eines zuvor verabschiedeten 10b5-1-Handelsplans durchgef眉hrt wurde. In Formular 4 ist verzeichnet, dass 667 Aktien zu je $80,86 gem盲脽 dem am 06.06.2025 angenommenen 10b5-1-Plan verkauft wurden, um geordnete Ver盲u脽erungen zu erm枚glichen. Nach dem gemeldeten Verkauf hielt Herr Malady wirtschaftlich 22.667 Aktien, darunter 5.192 nicht erfolgte Restricted Stock Units (RSU), die am 08.05.2025 gew盲hrt wurden und entweder am ersten Jahrestag der Gew盲hrung oder fr眉her bei der DexCom-Hauptversammlung 2026 verfallen/vesten.
- Transaction conducted under a 10b5-1 plan, which the filer states "allows the orderly disposition of shares"
- Continued beneficial ownership of 22,667 shares after the sale, indicating ongoing equity stake
- Disclosure includes vesting terms for 5,192 restricted stock units granted 05/08/2025
- Disposition of 667 shares at $80.86 reduced the reporting person鈥檚 direct holdings
- 5,192 RSUs are unvested, indicating a portion of reported ownership is not currently transferable
Insights
TL;DR Director sold a small number of shares under a pre-established 10b5-1 plan; remaining holdings include recently granted unvested RSUs.
The disclosure is a routine Section 16 transaction: Mr. Malady adopted a 10b5-1 plan on 06/06/2025 and executed a sale of 667 shares at $80.86 on 09/05/2025. The report shows continued beneficial ownership of 22,667 shares, including 5,192 unvested restricted stock units granted 05/08/2025 with a defined vesting condition tied to time or the 2026 annual meeting. For governance review, the filing documents adherence to an established trading plan and reports the nature and timing of equity grants and dispositions without other governance irregularities disclosed.
TL;DR Insider sale under a 10b5-1 plan, modest in size, with material detail on outstanding and unvested awards.
The Form 4 reports a disposition of 667 shares at $80.86 under a 10b5-1 plan adopted 06/06/2025. Post-transaction beneficial ownership is 22,667 shares, which explicitly includes 5,192 unvested RSUs granted 05/08/2025 that vest by time or the 2026 annual meeting. The filing provides clear transactional detail and award vesting terms useful for modeling insider liquidity and outstanding share counts, but it contains no earnings or operational data to affect financial forecasts directly.
Kyle Malady, direttore di DexCom, Inc. (DXCM), ha dichiarato la vendita di azioni ordinarie eseguita il 09/05/2025 nell'ambito di un piano di negoziazione 10b5-1 precedentemente adottato. Il Modulo 4 indica che sono state vendute 667 azioni al prezzo di $80,86 per azione conformemente al piano 10b5-1 adottato il 06/06/2025 per consentire disposizioni ordinate. Dopo la vendita riportata, il sig. Malady deteneva beneficiariamente 22.667 azioni, che includono 5.192 unit脿 di azioni vincolate non maturate (RSU) concesse il 05/08/2025 e che maturano alla scadenza del primo anniversario della concessione o, se anticipata, all'Assemblea Annuale degli Azionisti DexCom 2026.
Kyle Malady, director de DexCom, Inc. (DXCM), inform贸 la venta de acciones ordinarias realizada el 05/09/2025 en virtud de un plan de negociaci贸n 10b5-1 adoptado previamente. El Formulario 4 muestra que se vendieron 667 acciones a $80.86 por acci贸n conforme al plan 10b5-1 adoptado el 06/06/2025 para permitir disposiciones ordenadas. Tras la venta informada, el Sr. Malady pose铆a en beneficio 22,667 acciones, que incluyen 5,192 unidades restringidas de acciones no devengadas (RSU) otorgadas el 08/05/2025 y que devengar谩n en la fecha anterior entre el primer aniversario de la concesi贸n o la Junta Anual de Accionistas de DexCom de 2026.
DexCom, Inc.(DXCM) 鞚挫偓鞚� Kyle Malady電� 2025雲� 9鞗� 5鞚检棎 鞚挫爠鞐� 毂勴儩霅� 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 氤错喌欤茧ゼ 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 2025雲� 6鞗� 6鞚� 毂勴儩霅� 歆堨劀 鞛堧姅 觳橂秳鞚� 項堨毄頃橁赴 鞙勴暅 10b5-1 瓿勴殟鞐� 霐半澕 欤茧嫻 $80.86鞐� 667欤缄皜 毵る弰霅� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 毵り皝 鞚错泟 Malady 鞌姅 齑� 22,667欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞐赴鞐愲姅 2025雲� 5鞗� 8鞚检棎 攵�鞐悩鞏� 鞎勳 頇曥爼霅橃 鞎婌潃 5,192欤检潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� 韽暔霅橃柎 鞛堦碃, 頃措嫻 RSU電� 攵�鞐澕搿滊秬韯� 1欤茧厔 霕愲姅 DexCom鞚� 2026雲� 鞐半 欤检＜齑濏殞 欷� 雿� 鞚措ジ 鞁滌爯鞐� 旆摑霅╇媹雼�.
Kyle Malady, administrateur de DexCom, Inc. (DXCM), a d茅clar茅 une cession d'actions ordinaires r茅alis茅e le 05/09/2025 dans le cadre d'un plan de n茅gociation 10b5-1 adopt茅 ant茅rieurement. Le formulaire 4 indique que 667 actions ont 茅t茅 vendues 脿 80,86 $ par action conform茅ment au plan 10b5-1 adopt茅 le 06/06/2025 afin de permettre des cessions ordonn茅es. Apr猫s la vente signal茅e, M. Malady d茅tenait 脿 titre b茅n茅ficiaire 22 667 actions, qui comprennent 5 192 unit茅s d'actions restreintes non acquises (RSU) attribu茅es le 08/05/2025 et qui deviendront acquises au plus t么t 脿 la date du premier anniversaire de l'attribution ou lors de l'assembl茅e annuelle des actionnaires de DexCom en 2026.
Kyle Malady, Direktor von DexCom, Inc. (DXCM), meldete einen Verkauf von Stammaktien, der am 05.09.2025 im Rahmen eines zuvor verabschiedeten 10b5-1-Handelsplans durchgef眉hrt wurde. In Formular 4 ist verzeichnet, dass 667 Aktien zu je $80,86 gem盲脽 dem am 06.06.2025 angenommenen 10b5-1-Plan verkauft wurden, um geordnete Ver盲u脽erungen zu erm枚glichen. Nach dem gemeldeten Verkauf hielt Herr Malady wirtschaftlich 22.667 Aktien, darunter 5.192 nicht erfolgte Restricted Stock Units (RSU), die am 08.05.2025 gew盲hrt wurden und entweder am ersten Jahrestag der Gew盲hrung oder fr眉her bei der DexCom-Hauptversammlung 2026 verfallen/vesten.
FAQ
What shares did Kyle Malady sell in the Form 4 for DXCM?
Was the sale by Kyle Malady part of a 10b5-1 plan?
How many shares does Kyle Malady beneficially own after the reported transaction?
Does the Form 4 disclose any unvested awards for Kyle Malady?
At what price were the shares sold?
